A new study of pancreatic health after a diagnosis of diabetes is now open for recruitment in Wessex. The SAFE-D study is coordinated by the Early Diagnosis Team at Southampton Clinical Trials Unit.

In the Wessex area, people newly diagnosed with type 2 diabetes will be identified through the Specialist Diabetes Service Centres. They will invite eligible people via email or letter to take part in the study.

Interested individuals will be directed to the SAFE-D booking website where they can find out more about the study and register to attend a study visit at one of the research hubs. Currently Moorgreen Hospital is open and ready to see people, and hubs are opening in Portsmouth, Bournemouth and Weymouth soon.

This randomised study aims to evaluate a novel blood test (Avantect) to detect signals of the presence of pancreatic cancer in participants aged between 50 and 84 who have been diagnosed with type 2 diabetes within the last 6 months.

Participants in the intervention arm who have a detected Avantect test result will be referred by the study team for further pancreatic cancer investigations (MRI scan) at Southampton General Hospital or Royal Bournemouth & Christchurch Hospital.

For further information, visit the SAFE-D website